论文部分内容阅读
食管癌是我国常见的恶性肿瘤之一,死亡率高,预后较差,总5年生存率为20%左右,50%~60%的患者在就诊时已属晚期,中位生存期为4~8个月[1]。由于食管癌细胞的增殖周期长,对化疗药物不敏感,一般对晚期患者姑息治疗。既往常用的化疗方案有BLM+DDP+VLB,CTX+5-Fu MMC+5-Fu+VCR等,有效率
Esophageal cancer is one of the common malignant tumors in our country. The mortality is high and the prognosis is poor. The overall 5-year survival rate is about 20%. 50% -60% of patients have been treated at the advanced stage and the median survival time is 4 ~ 8 months [1]. Due to esophageal cancer cell proliferation cycle is not sensitive to chemotherapeutic drugs, usually for patients with advanced palliative treatment. Previously used chemotherapy programs are BLM + DDP + VLB, CTX + 5-Fu MMC + 5-Fu + VCR, etc., the effective rate